Lilly drops plan to seek expanded approval for Cymbalta

Eli Lilly and Co. withdrew its request for FDA approval to market its antidepressant Cymbalta for the treatment of chronic pain in the knee and back. The company said it intends to resubmit the application in the first half of next year, after it addresses the agency's concerns about Cymbalta's dosing and efficacy.

View Full Article in:

Reuters · Indianapolis Star (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President - Government Products
Health Alliance Plan
Detroit, MI
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Meridian Health Plan
Detroit, MI
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
President/Chief Executive Officer
Winston-Salem, NC